Boston Scientific is counting on its interventional cardiology and peripheral interventions businesses to lead it back to revenue growth in 2021.
“Our 2020 financials are clearly a negative outlier to our pre-pandemic six-year track record of excellent results,” CEO Michael Mahoney...